LU85550A1 - 2,5-disubstituees-4(3h)-pyrimidones ayant une activite antagoniste receptrice histamine h2,et compositions pharmaceutiques contenant de tels composes a titre d'ingredients actifs - Google Patents

2,5-disubstituees-4(3h)-pyrimidones ayant une activite antagoniste receptrice histamine h2,et compositions pharmaceutiques contenant de tels composes a titre d'ingredients actifs Download PDF

Info

Publication number
LU85550A1
LU85550A1 LU85550A LU85550A LU85550A1 LU 85550 A1 LU85550 A1 LU 85550A1 LU 85550 A LU85550 A LU 85550A LU 85550 A LU85550 A LU 85550A LU 85550 A1 LU85550 A1 LU 85550A1
Authority
LU
Luxembourg
Prior art keywords
compound
formula
pyrimidone
alkyl
pharmaceutically acceptable
Prior art date
Application number
LU85550A
Other languages
English (en)
French (fr)
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of LU85550A1 publication Critical patent/LU85550A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LU85550A 1983-09-21 1984-09-21 2,5-disubstituees-4(3h)-pyrimidones ayant une activite antagoniste receptrice histamine h2,et compositions pharmaceutiques contenant de tels composes a titre d'ingredients actifs LU85550A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53442683 1983-09-21
US06/534,426 US4772704A (en) 1983-09-21 1983-09-21 2,5-disubstituted-4(3H)-pyrimidones having histamine H2 -receptor antagonist activity

Publications (1)

Publication Number Publication Date
LU85550A1 true LU85550A1 (fr) 1985-06-04

Family

ID=24129972

Family Applications (1)

Application Number Title Priority Date Filing Date
LU85550A LU85550A1 (fr) 1983-09-21 1984-09-21 2,5-disubstituees-4(3h)-pyrimidones ayant une activite antagoniste receptrice histamine h2,et compositions pharmaceutiques contenant de tels composes a titre d'ingredients actifs

Country Status (36)

Country Link
US (1) US4772704A (es)
JP (1) JPH0643310B2 (es)
KR (1) KR900001198B1 (es)
AR (2) AR242385A1 (es)
AT (1) AT387965B (es)
AU (1) AU583479B2 (es)
BE (1) BE900652A (es)
CA (1) CA1260463A (es)
CH (1) CH665840A5 (es)
CS (1) CS249147B2 (es)
CY (1) CY1561A (es)
DD (1) DD226881A5 (es)
DE (1) DE3434578A1 (es)
DK (1) DK162987C (es)
ES (4) ES8607253A1 (es)
FI (1) FI83868C (es)
FR (1) FR2552082B1 (es)
GB (1) GB2146994B (es)
GR (1) GR80439B (es)
HK (1) HK73790A (es)
HU (1) HU193227B (es)
IE (1) IE58083B1 (es)
IL (1) IL72990A (es)
IT (1) IT1176739B (es)
LU (1) LU85550A1 (es)
NL (1) NL8402898A (es)
NO (1) NO161561C (es)
NZ (1) NZ209572A (es)
OA (1) OA07820A (es)
PT (1) PT79256B (es)
SE (1) SE463209B (es)
SG (1) SG60890G (es)
YU (1) YU45205B (es)
ZA (1) ZA847345B (es)
ZM (1) ZM4984A1 (es)
ZW (1) ZW16084A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2873340B2 (ja) * 1988-04-29 1999-03-24 武田薬品工業株式会社 抗生物質tan―1057,その製造法および用途
WO2022034121A1 (en) 2020-08-11 2022-02-17 Université De Strasbourg H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN151188B (es) * 1978-02-13 1983-03-05 Smith Kline French Lab
ES477520A1 (es) * 1978-02-25 1979-06-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevas penicilinas.
AU527202B2 (en) * 1978-04-11 1983-02-24 Smith Kline & French Laboratories Limited 2-aminopyrimidones
US4496567A (en) * 1978-11-13 1985-01-29 Smith Kline & French Laboratories Limited Phenyl alkylaminopyrimidones
US4521418A (en) * 1979-02-21 1985-06-04 Smith Kline & French Laboratories Limited Guanidinothiazolyl derivatives
AU531142B2 (en) * 1979-04-04 1983-08-11 Smith Kline & French Laboratories Limited 2 amino- pyimindones
CA1140129A (en) * 1979-08-21 1983-01-25 Ronald J. King 4-pyrimidone derivatives
ZW21281A1 (en) * 1980-10-01 1981-11-18 Smith Kline French Lab Amine derivatives
US4352933A (en) * 1981-02-06 1982-10-05 Smithkline Beckman Corporation Chemical methods and intermediates for preparing substituted pyrimidinones
NZ202797A (en) * 1981-12-28 1985-08-30 Lilly Co Eli Pyrimidine derivatives and pharmaceutical compositions
US4468399A (en) * 1981-12-28 1984-08-28 Eli Lilly And Company 2-[2-(2-Aminoalkyl-4-thiazolylmethylthio)alkyl]-amino-5-substituted-4-pyrimidones
GB8320505D0 (en) * 1983-07-29 1983-09-01 Smith Kline French Lab Chemical compounds
CA1275097A (en) * 1984-10-02 1990-10-09 Fujio Nohara Pyridyloxy derivatives

Also Published As

Publication number Publication date
DD226881A5 (de) 1985-09-04
AU583479B2 (en) 1989-05-04
AT387965B (de) 1989-04-10
GB2146994B (en) 1987-09-03
FR2552082B1 (fr) 1987-02-20
IT8422744A1 (it) 1986-03-20
DK162987B (da) 1992-01-06
IE58083B1 (en) 1993-06-30
OA07820A (fr) 1986-11-20
FI843643L (fi) 1985-03-22
SG60890G (en) 1990-09-07
FI843643A0 (fi) 1984-09-18
HUT35259A (en) 1985-06-28
ATA300984A (de) 1988-09-15
SE463209B (sv) 1990-10-22
NO161561C (no) 1989-08-30
YU161384A (en) 1987-12-31
KR900001198B1 (ko) 1990-02-28
NL8402898A (nl) 1985-04-16
FI83868B (fi) 1991-05-31
ES8704465A1 (es) 1987-04-01
DE3434578A1 (de) 1985-04-11
IT1176739B (it) 1987-08-18
NO843726L (no) 1985-03-22
DK162987C (da) 1992-06-01
ES544213A0 (es) 1987-04-01
AU3335184A (en) 1985-03-28
GB2146994A (en) 1985-05-01
ES8704155A1 (es) 1987-03-16
DK450484D0 (da) 1984-09-20
DK450484A (da) 1985-03-22
AR242789A1 (es) 1993-05-31
NO161561B (no) 1989-05-22
US4772704A (en) 1988-09-20
IE842406L (en) 1985-03-21
ZM4984A1 (en) 1985-05-21
AR242385A1 (es) 1993-03-31
ES8607253A1 (es) 1986-05-16
ZA847345B (en) 1985-06-26
NZ209572A (en) 1988-05-30
ES536054A0 (es) 1986-05-16
CY1561A (en) 1991-03-22
GR80439B (en) 1985-01-22
YU45205B (en) 1992-05-28
CH665840A5 (de) 1988-06-15
SE8404729L (sv) 1985-03-22
FI83868C (fi) 1991-09-10
IT8422744A0 (it) 1984-09-20
ES551500A0 (es) 1987-03-16
CS249147B2 (en) 1987-03-12
FR2552082A1 (fr) 1985-03-22
JPS6087271A (ja) 1985-05-16
HK73790A (en) 1990-09-28
GB8423863D0 (en) 1984-10-24
KR850002259A (ko) 1985-05-10
BE900652A (fr) 1985-03-21
ES8702897A1 (es) 1987-01-16
PT79256A (en) 1984-10-01
PT79256B (en) 1986-11-20
JPH0643310B2 (ja) 1994-06-08
ZW16084A1 (en) 1985-01-16
CA1260463A (en) 1989-09-26
ES551501A0 (es) 1987-01-16
SE8404729D0 (sv) 1984-09-20
HU193227B (en) 1987-08-28
IL72990A (en) 1990-07-12

Similar Documents

Publication Publication Date Title
FR2505835A1 (fr) Nouvelles 1,2-diaminocyclobutene-3,4-diones, leur procede de preparation et composition pharmaceutique les contenant
FR2823209A1 (fr) Nouvelles thiohydantoines et leur utilisation en therapeutique
CH639653A5 (fr) Aminothiazoles et composition pharmaceutique les contenant.
CA2150162C (fr) Nouveau n-pyridyl carboxamides et derives, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
IL41825A (en) Pyridine derivatives their preparation and pharmaceutical compositions containing them
BE898278A (fr) Benzoxazines antipsychotiques.
EP2887804B1 (en) Cycloalkanyl[b]indoles useful as glp-1 modulators
JPH0233031B2 (es)
CH641759A5 (fr) Phenethanolamines et composition pharmaceutique antineoplastique les contenant.
FR2489823A1 (fr) Nouvelles n-((4-(3-pyridyle substitue en position 3)-piperazino)alkyl)azaspirodecanediones, leur procede de preparation et medicament les contenant
KR840001019B1 (ko) 치환된 푸란의 제조방법
DK158460B (da) Analogifremgangsmaade til fremstilling af substituerede oxocarboxylsyrer
KR100372312B1 (ko) 신규의히드록시믹산유도체,그를포함한약제학적조성물및그의제조방법
LU85550A1 (fr) 2,5-disubstituees-4(3h)-pyrimidones ayant une activite antagoniste receptrice histamine h2,et compositions pharmaceutiques contenant de tels composes a titre d'ingredients actifs
FR2581064A1 (fr) Derive antipsychotique a base de 8-(4-(4-(1-exo-1,2-benzisothiazol-3-yl)-1-piperazinyl)-butyl)-8-azaspiro(4,5)decane-7,9-dione et son procede de preparation
CN102086212A (zh) 抗真菌剂-2,3,4,5-四氢-4H-苯并[b]噻喃并[4,3-c]吡唑-2-甲酰胺衍生物
EP0180500A1 (fr) Dérivés de thiéno et furo - [2,3-c]pyrroles, procédés de préparation et médicaments les contenant
FR2499853A1 (fr) Agents cardiotoniques, a base de derives du 5-phenylthiazole et composition pharmaceutique contenant un tel agent
JPS6322069A (ja) 複素多環式芳香族化合物
FR2543952A1 (fr) Composes hydrocarbones heterocycliques appartenant aux series indoliques et leur application pharmacologique
JPS61260018A (ja) 抗アレルギ−剤
EP1007522B1 (fr) 2- 4-[4-(4,5-dichloro-2-methylimidazol-1-yl)butyl]piperazin-1-yl -5-fluoropyrimidine, sa preparation et son utilisation therapeutique
JPS6026386B2 (ja) 新規イソインド−ル化合物
JPH0262554B2 (es)
EP0008269A1 (fr) Nouveaux médicaments contenant, à titre de substance active, des composés de type benzènesulfone, nouveaux composés de ce type et procédé pour leur préparation